FDA mulls compounding for peptides previously flagged over safety risks BioSpace The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Before and After: 1 Amazing Transformation BPC 157 Banned: Key Facts on the Latest FDA Decision Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law